Back

PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Lipid-lowering by PCSK9 modulation: what’s new? Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Dennis Kannenkeril

University Hospital Erlangen, Erlangen (Germany)

4 More presentations in this session

Presentation thumbnail
Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial
Doctor L. Raber (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data
Professor M. Svensson (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering by PCSK9 modulation: what’s new?

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
thumbnail
Congress Presentation
Effect of evolocumab on platelet function in patients with acute coronary syndromes. An analysis of the randomized, double-blind, placebo-controlled EVOPACS Trial
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources